Artivion receives FDA PMA approval for AMDS Hybrid Prosthesis
Artivion (NYSE:AORT) announced that the U.S. Food and Drug Administration has granted premarket approval for its AMDS Hybrid Prosthesis for the treatment of acute DeBakey Type I aortic dissections with malperfusion.










